Form 4: ADMA Biologics Insider Sells Shares for Tax Withholding

Kaitlin M. Kestenberg-Messina, COO and SVP of Compliance at ADMA Biologics, reported a transaction involving 20,362 shares of common stock on April 1, 2026, primarily for tax withholding purposes.

Summary

• Kaitlin M. Kestenberg-Messina, the COO and SVP of Compliance at ADMA BIOLOGICS, INC., reported a transaction on April 1, 2026.
• This transaction involved 20,362 shares of common stock.
• The shares were withheld by the Issuer to satisfy mandatory tax withholding requirements upon the vesting of restricted stock units (RSUs).
• This is not an open market sale of securities.
• Following this transaction, Kestenberg-Messina beneficially owns 446,238 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard tax-related transaction for restricted stock units and does not provide new financial information or strategic insights.

Positives

• The transaction is a standard tax withholding event upon RSU vesting, not an indication of insider selling due to negative outlook.
• The reporting person continues to hold a significant number of shares (446,238) after the transaction.

Negatives

• A portion of the reporting person's holdings were used to cover tax obligations, reducing their direct share count.

Future Outlook

No specific future outlook or guidance is provided in this Form 4 filing, which solely reports a change in beneficial ownership due to tax withholding.

Industry Context

StockSavvy.ai notes that Form 4 filings, like this one from ADMA Biologics, are routine disclosures of insider transactions. The nature of this transaction, a tax withholding upon RSU vesting, is common and generally does not signal a change in management's view of the company's prospects.

Stakeholder Impact

• Shareholders: No direct impact on share price is expected from this routine tax withholding transaction. The reporting person's overall beneficial ownership remains substantial.

Key Dates

Keywords

ADMA Biologics, Form 4, Insider Transaction, Stock Withholding, RSU Vesting, Kaitlin Kestenberg-Messina, SEC Filing